Arbovirus Testing Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Arbovirus Testing Market size was estimated at USD 1.21 Billion in 2025 and is projected to grow at a 5.8% CAGR from 2026 to 2035, exceeding USD 2.13 Billion by 2035. The industry revenue for 2026 is calculated at USD 1.27 billion.
Get more details on this report
Request Free Sample ReportArbovirus Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 44.10% share in 2025, supported by established diagnostic laboratory networks, advanced healthcare infrastructure, and routine infectious disease surveillance using molecular and serological testing.
- Asia Pacific is projected to grow at a 6.55% CAGR as expanding public health surveillance, recurring mosquito-borne disease outbreaks, and greater demand for early diagnosis increase testing adoption.
Segment Momentum
- ELISA-based tests lead with a 51.62% share due to scalable, cost-effective screening and established use in routine diagnostics, enabling efficient processing of large sample volumes in clinical laboratories.
- RT-PCR tests are the fastest-growing segment as demand increases for precise molecular detection, offering higher diagnostic confidence and improved ability to identify arboviral infections early.
Market Expansion Drivers
- Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance.
- Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening.
- WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading players in the arbovirus testing market include Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Merck KGaA (Germany), Agilent Technologies, Inc. (United States), bioMérieux SA (France).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As dengue and Zika cases become more frequent and geographically widespread, healthcare systems are under pressure to distinguish arboviral infections quickly from other febrile illnesses, especially during seasonal surges and localized outbreaks. This is driving demand for the arbovirus testing market by increasing procurement of rapid diagnostic kits, PCR assays, and surveillance-oriented testing workflows that can support early case identification and public health response. Hospitals, public laboratories, and vector-control authorities rely on faster diagnostic turnaround to guide triage, confirm outbreak clusters, and trigger containment measures, which in practice raises testing volumes and supports broader adoption of decentralized and high-throughput arbovirus testing platforms.
Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening
Routine screening needs in hospitals and diagnostic laboratories are supporting market expansion for the arbovirus testing market through wider use of ELISA-based assays, which fit established laboratory workflows and allow cost-effective processing of larger sample volumes. Their practical appeal comes from compatibility with existing equipment, technician familiarity, and the ability to standardize serology testing for suspected dengue, Zika, and related infections without requiring highly specialized molecular infrastructure for every case. As a result, laboratories increasingly incorporate ELISA into frontline screening algorithms, reserving more complex confirmatory methods for selected samples and reinforcing steady reagent and kit consumption.
WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives
International health programs are driving market development in the arbovirus testing market by improving laboratory capacity, procurement systems, and testing protocols in regions where arboviral disease burden is highest. When WHO-led and donor-backed initiatives support reference lab networks, workforce training, assay validation, and harmonized diagnostic guidelines, they reduce variability in testing practices and make adoption decisions easier for ministries of health and public health laboratories. This creates more consistent demand for approved assays and supporting instruments, while standardization efforts help integrate arbovirus diagnostics into broader neglected tropical disease and outbreak preparedness frameworks.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of arbovirus infections | 1.80% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Adoption of advanced diagnostic testing | 2.00% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Expansion of healthcare and lab infrastructure in emerging markets | 2.00% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Rising dengue and Zika incidence driving demand for rapid outbreak diagnostics and surveillance | 2.10% | High | Asia Pacific, Latin America | High | Near Term |
| Expanding use of ELISA-based diagnostic testing in clinical laboratories for routine screening | 1.90% | Moderate | North America | High | Near Term |
| WHO and global health programs strengthening diagnostic infrastructure and NTD testing standardization initiatives | 1.70% | High | Africa, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading position in the arbovirus testing market in 2025, accounting for a 44.10% share. This leadership is supported by established diagnostic laboratory networks, broad access to molecular and serological testing, and routine integration of infectious disease surveillance into public health practice. The region’s market activity is reinforced by faster test deployment through well-developed healthcare infrastructure and consistent use of confirmatory testing in hospital, reference lab, and government settings where vector-borne disease monitoring is closely managed.
Asia Pacific is projected to expand at a 6.55% CAGR over the forecast period in the arbovirus testing market, driven by rising testing demand in areas exposed to recurring mosquito-borne disease outbreaks and expanding public health detection efforts. Growth is being fueled by the practical need for earlier diagnosis, wider surveillance coverage, and improved access to testing across densely populated and climatically vulnerable locations. As healthcare systems increase their focus on outbreak identification and response, adoption is accelerating across laboratories and care settings that require timely detection to manage disease spread.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Diagnostic Preparedness ProgramsGermany is strengthening arbovirus testing capabilities through improved laboratory preparedness and vector-borne disease monitoring initiatives. The market prioritizes accurate diagnostic tools that support timely identification of imported and locally transmitted infections.
France 🇫🇷
Integrated Disease DetectionFrance maintains active interest in arbovirus diagnostics due to ongoing monitoring of mosquito-borne disease risks in metropolitan and overseas territories. Diagnostic providers are focusing on testing solutions that enable efficient surveillance and outbreak containment strategies.
Italy 🇮🇹
Seasonal Surveillance CapacityItaly is expanding arbovirus testing capabilities to support seasonal monitoring and early identification of vector-borne infections. Public health authorities and laboratories are increasingly adopting advanced diagnostic technologies to improve response coordination and disease tracking.
Japan 🇯🇵
Vector Monitoring InitiativesJapan places emphasis on surveillance and diagnostic readiness for mosquito-borne diseases, particularly in densely populated regions. Healthcare institutions are increasingly adopting sensitive testing methods that facilitate early detection and outbreak management.
South Korea 🇰🇷
Rapid Response DiagnosticsSouth Korea is enhancing arbovirus testing infrastructure to support faster identification of vector-borne infections and strengthen public health response systems. The market is seeing growing adoption of molecular assays and integrated disease surveillance programs.
United States 🇺🇸
Public Health SurveillanceThe U.S. arbovirus testing market is shaped by increasing surveillance efforts and the need for rapid diagnostics during seasonal outbreaks. Laboratories and healthcare providers in the U.S. are expanding molecular testing capabilities to improve detection and epidemiological monitoring.
Segment Leadership and Growth Trends
Arbovirus Testing Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportELISA-based Tests held a 51.62% share of the arbovirus testing market in 2025, reflecting their entrenched role in routine diagnostic workflows where laboratories need practical, scalable, and cost-conscious testing methods. Their leadership is underpinned by broad familiarity across clinical settings, established use in high-volume screening, and the operational ease of integrating these assays into standard laboratory processes. In the arbovirus testing market, this makes ELISA-based Tests a dependable choice where turnaround efficiency and testing throughput matter more than adopting newer molecular formats for every case.
RT-PCR Based Tests are the fastest-growing segment in the arbovirus testing market because demand is rising for methods that can support more precise and earlier-stage detection in settings where diagnostic certainty is increasingly important. Growth is being reinforced by the need to distinguish arboviral infections with greater analytical confidence, especially as testing requirements become more sensitive to timely identification and clinical decision-making. Compared with conventional serology-led approaches, RT-PCR Based Tests are gaining momentum where laboratories and healthcare systems are placing higher value on molecular confirmation and refined detection capability.
End Use Segment Analysis: Diagnostic Laboratories (Largest Segment) vs Research Centers (Fastest-Growing Segment)
Diagnostic Laboratories accounted for the largest share of the arbovirus testing market in 2025, supported by their central role in handling routine patient testing and processing large sample volumes within established healthcare networks. Their leadership comes from day-to-day diagnostic demand, existing laboratory infrastructure, and their position as the primary point of test execution for suspected arboviral infections. In the arbovirus testing market, these practical service-delivery dynamics keep Diagnostic Laboratories at the forefront of end-use demand.
Research Centers represent the fastest-growing end-use segment in the arbovirus testing market as expanding scientific focus on arboviral surveillance, detection methods, and disease characterization continues to increase testing activity in research environments. Their momentum is tied to the need for deeper investigative work around pathogen behavior and assay performance, which creates stronger demand for advanced and exploratory testing use than in routine diagnostic settings. Relative to established clinical end users, Research Centers are growing faster because their testing demand is being shaped by active study programs and evolving research priorities rather than stable everyday diagnostic volumes.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | ELISA-based Tests, RT-PCR Based Tests, Others | ELISA-based Tests | RT-PCR Based Tests |
| End Use | Diagnostic Laboratories, Hospitals, Research Centers, Others | Diagnostic Laboratories | Research Centers |
Competitive Landscape and Market Positioning
1. Abbott Laboratories (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. F. Hoffmann-La Roche Ltd (Switzerland)
4. Siemens Healthineers AG (Germany)
5. QIAGEN N.V. (Netherlands)
6. Bio-Rad Laboratories Inc. (United States)
7. EUROIMMUN Medizinische Labordiagnostika AG (Germany)
8. Merck KGaA (Germany)
9. Agilent Technologies Inc. (United States)
10. bioMérieux SA (France)
The arbovirus testing market is advancing through improved diagnostic accuracy and faster detection technologies. Enhanced testing platforms are enabling quicker outbreak identification and response. New diagnostic solution launches are improving laboratory efficiency and reliability. Collaborative research initiatives are further strengthening detection capabilities, supporting the arbovirus testing market in addressing evolving infectious disease challenges.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Astellas Pharma Inc. | May-23 | Astellas Pharma Inc. committed to supporting Phase III of the Global Health Innovative Technology Fund (GHIT Fund), collaborating with cross-sector funding partners to advance global health innovation. The initiative indirectly supports development pathways for infectious disease diagnostics, reinforcing broader ecosystem funding for arbovirus-related testing and surveillance innovation. |
| Anitoa Systems | May-22 | Anitoa Systems introduced a portable RT-PCR molecular diagnostic platform for dengue detection using the Maverick qPCR instrument and lyophilized multiplex RT-PCR reagents. The solution enables rapid identification of dengue infections and expands portable molecular testing capabilities, strengthening point-of-care arbovirus diagnostic accessibility. |
| Mylab | Jul-22 | Mylab launched the PathoDetect Extended Monsoon Fever Panel, a multiplex RT-PCR assay designed to detect multiple arboviruses and related infections including dengue, zika, and malaria. The compact test system delivers results within approximately two hours and supports scaled diagnostic capacity for outbreak surveillance and infectious disease management. |
| FDA | Jan-25 | The U.S. FDA issued streamlined regulatory guidance for emerging pathogen in vitro diagnostic approvals, reducing barriers for arbovirus testing solutions. The policy is expected to accelerate commercialization timelines for new diagnostic technologies and expand market entry opportunities for RT-PCR and other molecular test platforms. |
| FDA | Nov-23 | The FDA approved IXCHIQ, the first chikungunya vaccine in the United States, influencing arbovirus testing demand by increasing pre- and post-vaccination diagnostic requirements. The approval contributes to evolving clinical workflows for arbovirus surveillance and reinforces demand for confirmatory and differential diagnostic testing solutions. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Arbovirus Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Arbovirus Testing Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much is the arbovirus testing market worth?
What is the anticipated CAGR of the arbovirus testing industry?
How is the shift toward molecular confirmation reshaping diagnostic workflows in the arbovirus testing market?
What is driving the expansion of surveillance-driven testing demand in arbovirus diagnostics?
Why do ELISA-based tests dominate the arbovirus testing market?
What is driving growth in RT-PCR based testing?
Why does North America lead the arbovirus testing market?
What is fueling arbovirus testing market growth in Asia Pacific?
What are the key competitors in the arbovirus testing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization